### Philippines

**Population 2018**

<table>
<thead>
<tr>
<th>Number (thousands)</th>
<th>Rate (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>107 million</td>
<td></td>
</tr>
</tbody>
</table>

**Estimates of TB burden°, 2018**

<table>
<thead>
<tr>
<th>Total TB incidence</th>
<th>591 (332–924)</th>
<th>554 (311–866)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIV-positive TB incidence</td>
<td>10 (4.1–19)</td>
<td>9.4 (3.8–17)</td>
</tr>
<tr>
<td>MDR-RR-TB incidence°°</td>
<td>16 (7.7–32)</td>
<td>17 (7.3–30)</td>
</tr>
<tr>
<td>HIV-negative TB mortality</td>
<td>26 (22–30)</td>
<td>24 (20–28)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>0.6 (0–4.2)</td>
<td>0.57 (0–4)</td>
</tr>
</tbody>
</table>

**Estimated proportion of TB cases with MDR/RR-TB, 2018**

- **New cases**: 1.7% (1.1–2.5)
- **Previously treated cases**: 16% (19–20)

**TB case notifications, 2018**

- **Total new and relapse**: 371,668
  - % tested with rapid diagnostics at time of diagnosis: 36%
  - % with known HIV status: 27%
  - % pulmonary: 98%
  - % bacteriologically confirmed°°°: 36%
  - % children aged 0–14 years: 12%
  - % women: 30%
  - % men: 58%
- **Total cases notified**: 382,543

**Universal health coverage and social protection**

- **TB treatment coverage (notified/estimated incidence), 2018**: 63% (40–110)
- **TB patients facing catastrophic total costs, 2017**: 35% (33–37)
- **TB case fatality ratio (estimated mortality/estimated incidence), 2018**: 5% (3–7)

**TB/HIV care in new and relapse TB patients, 2018**

- Patients with known HIV status who are HIV-positive: 1,477 (1%)
  - on antiretroviral therapy: 1,350 (91%)

**Drug-resistant TB care, 2018**

- % of bacteriologically confirmed TB cases tested for rifampicin resistance °°°
  - New cases: <1%
  - Previously treated cases: 24%

**Laboratory-confirmed cases**

- MDR/RRTB: 7,276
- XDR-TB: 52

**Patients started on treatment**

- MDR/RRTB: 6,125
- XDR-TB: 52

**MDR/RRTB-TB cases tested for resistance to second-line drugs**

- 2,095

**Treatment success rate and cohort size**

- **New and relapse cases registered in 2017**: 91% of 315,923
- **Previously treated cases, excluding relapse, registered in 2017**: 82% of 9,486
- **HIV-positive TB cases registered in 2017**: 83% of 1,258
- **MDR-RRTB cases started on second-line treatment in 2016**: 58% of 5,071
- **XDR-TB cases started on second-line treatment in 2016**: 20% of 10

**TB preventive treatment, 2018**

- % of HIV-positive people (newly enrolled in care) on preventive treatment: 52%
- % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment: 9.4% (8.7–10)

**TB financing, 2019**

- **National TB budget (US$ millions)**: 205

- Funding source: 12% domestic, 25% international, 63% unfunded

° Ranges represent uncertainty intervals
°° MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
°°° Calculated for pulmonary cases only
* Includes cases with unknown previous TB treatment history
** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

Generated: 2020-02-03  
Data: www.who.int/tb/data